Volume 14 Issue 6
Nov.  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(6): 789-796
Wang Guoying, He Caihua. Progress in liver transplantation for intrahepatic cholangiocarcinoma[J]. ORGAN TRANSPLANTATION, 2023, 14(6): 789-796. doi: 10.3969/j.issn.1674-7445.2023144
Citation: Wang Guoying, He Caihua. Progress in liver transplantation for intrahepatic cholangiocarcinoma[J]. ORGAN TRANSPLANTATION, 2023, 14(6): 789-796. doi: 10.3969/j.issn.1674-7445.2023144
shu

Progress in liver transplantation for intrahepatic cholangiocarcinoma

doi: 10.3969/j.issn.1674-7445.2023144

  • Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

More Information
  • Corresponding author: Wang Guoying, Email: wanggy3@126.com
  • Received Date: 2023-07-22
    Available Online: 2023-08-25
  • Publish Date: 2023-11-09
    Abstract
  • Intrahepatic cholangiocarcinoma (ICC) is a primary malignant tumor of the liver, secondary to hepatocellular carcinoma, and its incidence tends to elevate worldwide. Hepatectomy is the optimal surgical regimen for ICC patients. ICC is considered as a contraindication for liver transplantation due to high tumor recurrence rate and poor survival outcome. At present, multiple significant progresses have been made in liver transplantation for ICC. For strictly-selected ICC patients, liver transplantation or liver transplantation after neoadjuvant therapy has achieved encouraging survival outcomes. Meantime, with the improvement of prognostic risk stratification of liver transplantation for ICC, the inclusion criteria of ICC candidates undergoing liver transplantation will be further optimized. In addition, the advancement of modern multi-mode comprehensive treatment of ICC will further guide the selection of neoadjuvant therapy before liver transplantation for ICC. The application of immune checkpoint inhibitors in ICC before liver transplantation is also an important research direction in the future. In this article, clinical prognosis of liver transplantation for ICC, prognostic risk factors and inclusion criteria of ICC candidates undergoing liver transplantation, and the ongoing trials and existing challenges were summarized, aiming to provide reference for liver transplantation for ICC and improve the quality of life for ICC patients.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2]
    AN L, ZHENG R, ZHANG S, et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries[J]. Hepatobiliary Surg Nutr, 2023, 12(1): 45-55. DOI: 10.21037/hbsn-21-75.
    [3]
    中国抗癌协会肝癌专业委员会胆管癌协作组. 原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21(10): 1269-1301. DOI: 10.3760/cma.j.cn115610-20220829-00476.

    Biliary Cancer Collaborative Group of the Liver Cancer Professional Committee of the China Anti Cancer Association. Chinese expert consensus on management of intrahepatic cholangiocarcinoma (2022 edition)[J]. Chin J Dig Surg, 2022, 21(10): 1269-1301. DOI: 10.3760/cma.j.cn115610-20220829-00476.
    [4]
    MAZZAFERRO V, GORGEN A, ROAYAIE S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72(2): 364-377. DOI: 10.1016/j.jhep.2019.11.020.
    [5]
    SAPISOCHIN G, IVANICS T, HEIMBACH J. Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time? [J]. Hepatology, 2022, 75(2): 455-472. DOI: 10.1002/hep.32258.
    [6]
    KODALI S, SAHARIA A, GHOBRIAL RM. Liver transplantation and intrahepatic cholangiocarcinoma: time to go forward again? [J]. Curr Opin Organ Transplant, 2022,27(4):320-328. DOI: 10.1097/MOT.0000000000000983.
    [7]
    ZIOGAS IA, GIANNIS D, ECONOMOPOULOS KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates[J]. Transplantation, 2021, 105(10): 2263-2271. DOI: 10.1097/TP.0000000000003539.
    [8]
    HARA T, EGUCHI S, YOSHIZUMI T, et al. Incidental intrahepatic cholangiocarcinoma in patients undergoing liver transplantation: a multi-center study in Japan[J]. J Hepatobiliary Pancreat Sci, 2021, 28(4): 346-352. DOI: 10.1002/jhbp.896.
    [9]
    TAKAHASHI K, OBEID J, BURMEISTER CS, et al. Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis[J]. Ann Transplant, 2016, 21: 208-215. DOI: 10.12659/aot.895936.
    [10]
    DE MARTIN E, RAYAR M, GOLSE N, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis[J]. Liver Transpl, 2020, 26(6): 785-798. DOI: 10.1002/lt.25737.
    [11]
    HUE JJ, ROCHA FG, AMMORI JB, et al. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: an analysis of the National Cancer Database[J]. J Surg Oncol, 2021, 123(4): 949-956. DOI: 10.1002/jso.26370.
    [12]
    KIM P, LITTAU M, BAKER TB, et al. Intrahepatic cholangiocarcinoma: is there a role for liver transplantation? [J]. Surgery, 2022, 171(3): 741-746. DOI: 10.1016/j.surg.2021.09.034.
    [13]
    HUANG G, SONG W, ZHANG Y, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis[J]. Sci Rep, 2023, 13(1): 10630. DOI: 10.1038/s41598-023-37896-2.
    [14]
    SAPISOCHIN G, RODRÍGUEZ DE LOPE C, GASTACA M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? [J]. Am J Transplant, 2014, 14(3): 660-667. DOI: 10.1111/ajt.12591.
    [15]
    SAPISOCHIN G, FACCIUTO M, RUBBIA-BRANDT L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4): 1178-1188. DOI: 10.1002/hep.28744.
    [16]
    GUPTA R, TOGASHI J, AKAMATSU N, et al. Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review[J]. Surg Today, 2017, 47(8): 908-917. DOI: 10.1007/s00595-017-1472-3.
    [17]
    JUNG DH, HWANG S, SONG GW, et al. Clinicopathological features and prognosis of intrahepatic cholangiocarcinoma after liver transplantation and resection[J]. Ann Transplant, 2017, 22: 42-52. DOI: 10.12659/aot.901504.
    [18]
    SAPISOCHIN G, DE LOPE CR, GASTACA M, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study[J]. Ann Surg, 2014, 259(5): 944-952. DOI: 10.1097/SLA.0000000000000494.
    [19]
    LEE DD, CROOME KP, MUSTO KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma[J]. Liver Transpl, 2018, 24(5): 634-644. DOI: 10.1002/lt.25052.
    [20]
    吴凤东, 史斌. 肝内胆管癌肝移植及其综合治疗[J]. 器官移植, 2021, 12(3): 344-350. DOI: 10.3969/j.issn.1674-7445.2021.03.014.

    WU FD, SHI B. Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma[J]. Organ Transplant, 2021, 12(3): 344-350. DOI: 10.3969/j.issn.1674-7445.2021.03.014.
    [21]
    HONG JC, JONES CM, DUFFY JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center[J]. Arch Surg, 2011, 146(6): 683-689. DOI: 10.1001/archsurg.2011.116.
    [22]
    LUNSFORD KE, JAVLE M, HEYNE K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018, 3(5): 337-348. DOI: 10.1016/S2468-1253(18)30045-1.
    [23]
    ABDELRAHIM M, AL-RAWI H, ESMAIL A, et al. Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: case-series[J]. Curr Oncol, 2022, 29(5): 3585-3594. DOI: 10.3390/curroncol29050290.
    [24]
    ABDELRAHIM M, ESMAIL A, XU J, et al. Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation: an institution experience[J]. Front Oncol, 2022, 12: 908687. DOI: 10.3389/fonc.2022.908687.
    [25]
    RAYAR M, LEVI SANDRI GB, HOUSSEL-DEBRY P, et al. Multimodal therapy including Yttrium-90 radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma[J]. J Gastrointestin Liver Dis, 2016, 25(3): 401-404. DOI: 10.15403/jgld.2014.1121.253.y90.
    [26]
    MCMILLAN RR, JAVLE M, KODALI S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma[J]. Am J Transplant, 2022, 22(3): 823-832. DOI: 10.1111/ajt.16906.
    [27]
    ITO T, BUTLER JR, NOGUCHI D, et al. A 3-decade, single-center experience of liver transplantation for cholangiocarcinoma: impact of era, tumor size, location, and neoadjuvant therapy[J]. Liver Transpl, 2022, 28(3): 386-396. DOI: 10.1002/lt.26285.
    [28]
    孙大伟,蒋文涛,钟林,等. 肝移植治疗肝内胆管细胞癌临床疗效的多中心研究[J]. 中华消化外科杂志, 2023,22(2):230-235. DOI: 10.3760/cma.j.cn115610- 20221219-00753.

    SUN DW, JIANG WT, ZHONG L, et al. Clinical efficacy of liver transplantation for intrahepatic cholangiocarcinoma: a multicenter study[J]. Chin J Dig Surg, 2023,22(2):230-235. DOI: 10.3760/cma.j.cn115610-20221219-00753.
    [29]
    KODALI S, CONNOR AA, THABET S, et al. Comparison of resection versus liver transplantation for intrahepatic cholangiocarcinoma: past, present, and future directions[J]. Hepatobiliary Pancreat Dis Int, 2023, DOI: 10.1016/j.hbpd.2023.07.007[Epub ahead of print
    [30]
    吕国悦, 孙大伟. 肝内胆管细胞癌肝移植治疗的预后分析与策略选择[J]. 中华消化外科杂志, 2023, 22(2): 187-194. DOI: 10.3760/cma.j.cn115610-20221123-00707.

    LYU GY, SUN DW. Prognosis analysis and strategies selection in liver transplantation for intrahepatic cholangio-carcinoma[J]. Chin J Dig Surg, 2023, 22(2): 187-194. DOI: 10.3760/cma.j.cn115610-20221123-00707.
    [31]
    HONG JC, PETROWSKY H, KALDAS FM, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma[J]. J Am Coll Surg, 2011, 212(4): 514-521. DOI: 10.1016/j.jamcollsurg.2010.12.005.
    [32]
    DUIGNAN S, MAGUIRE D, RAVICHAND CS, et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience[J]. HPB (Oxford), 2014, 16(1): 91-98. DOI: 10.1111/hpb.12082.
    [33]
    REN A, LI Z, CHENG P, et al. Systemic immune-inflammation index is a prognostic predictor in patients with intrahepatic cholangiocarcinoma undergoing liver transplantation[J]. Mediators Inflamm, 2021: 6656996. DOI: 10.1155/2021/6656996.
    [34]
    杨发才,游川,雷正清,等. 肿瘤负荷评分联合淋巴结分期对肝内胆管细胞癌患者术后生存预测价值[J/CD]. 中华肝脏外科手术学电子杂志, 2023,12(4):389-394. DOI: 10.3877/cma.j.issn.2095-3232.2023.04.006.

    YANG FC, YOU C, LEI ZQ, et al. Predictive value of tumor burden score combined with lymph node staging for postoperative survival of intrahepatic cholangiocarcinoma patients[J/CD]. Chin J Hepatic Surg (Electr Edit), 2023,12(4):389-394. DOI: 10.3877/cma.j.issn.2095-3232.2023.04.006.
    [35]
    LEI Z, MA W, SI A, et al. Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma[J]. Aliment Pharmacol Ther, 2023, 58(6): 611-622. DOI: 10.1111/apt.17623.
    [36]
    ZHU SG, LI HB, DAI TX, et al. Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: a case report[J]. World J Clin Cases, 2022, 10(27): 9743-9749. DOI: 10.12998/wjcc.v10.i27.9743.
    [37]
    Liver transplantation for early intrahepatic cholangiocarcinoma (LT for iCCA) [EB/OL]. [2023-07-01]. https://classic.clinicaltrials.gov/ct2/show/NCT02878473?term=NCT02878473.
    [38]
    Liver transplantation for stable, advanced intrahepatic cholangiocarcinoma[EB/OL]. [2023-07-01]. https://clinicaltrials. gov/study/NCT04195503?term=NCT04195503.
    [39]
    Liver transplantation for non-resectable intrahepatic cholangiocarcinoma: a prospective exploratory trial (TESLA Trial) [EB/OL]. [2023-07-01]. https://clinicaltrials.gov/study/NCT04556214?term=NCT04556214.
    [40]
    宋方彬, 李善宝, 徐军明. 肝移植治疗肝内胆管癌的现状与挑战[J]. 肝脏, 2022, 27(5): 514-515, 520. DOI: 10.3969/j.issn.1008-1704.2022.05.005.

    SONG FB, LI SB, XU JM. Current status and challenges of liver transplantation for intrahepatic cholangiocarcinoma[J]. Chin Hepatol, 2022, 27(5): 514-515, 520. DOI: 10.3969/j.issn.1008-1704.2022.05.005.
    [41]
    SAPISOCHIN G, JAVLE M, LERUT J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference[J]. Transplantation, 2020, 104(6): 1125-1130. DOI: 10.1097/TP.0000000000003212.
    [42]
    BOERNER T, DRILL E, PAK LM, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma[J]. Hepatology, 2021, 74(3): 1429-1444. DOI: 10.1002/hep.31829.
    [43]
    MOECKLI B, IVANICS T, CLAASEN M, et al. Recent developments and ongoing trials in transplant oncology[J]. Liver Int, 2020, 40(10): 2326-2344. DOI: 10.1111/liv.14621.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (427) PDF downloads(52) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return